Antinucleolar antibodies

Sabine Oertelt, Mauro Podda, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Antinucleolar antibodies (ANoAs) react against a wide range of nucleolar structures, virtually targeting every functional step of ribosomal transcription. Traditionally detected by immunofluorescence, their presence is confirmed by immunoprecipitation and in some cases by Enzyme-linked immunosorbent assay (ELISA). The patterns detected by immunofluorescence are: speckled, associated with reactivity against RNA polymerase; homogeneous, characteristic of anti-PM-Scl and anti-To/Th antibody positivity; and clumpy, observed in cells in metaphase and associated with antibodies against snoRNPs. ANoAs are prevalently associated with systemic sclerosis (SSc), but are detectable in small numbers of patients with other autoimmune diseases and carcinomas. The prevalence of different ANoAs in the serum of patients with SSc varies, but never exceeds 20-30%, making these antibodies not useful for primary diagnosis of the disease. Nonetheless, specific clinical associations for various subtypes of ANoAs suggest that these antibodies are potentially valuable diagnostic markers, especially for high-risk patient groups.

Original languageEnglish (US)
Title of host publicationAutoantibodies
PublisherElsevier Inc.
Pages135-139
Number of pages5
ISBN (Print)9780444527639
DOIs
StatePublished - 2007

Fingerprint

Antibodies
Systemic Scleroderma
Fluorescent Antibody Technique
Small Nucleolar Ribonucleoproteins
Immunosorbents
DNA-Directed RNA Polymerases
Transcription
Metaphase
Immunoprecipitation
Autoimmune Diseases
Assays
Enzyme-Linked Immunosorbent Assay
Carcinoma
Enzymes
Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oertelt, S., Podda, M., & Gershwin, M. E. (2007). Antinucleolar antibodies. In Autoantibodies (pp. 135-139). Elsevier Inc.. https://doi.org/10.1016/B978-044452763-9/50022-6

Antinucleolar antibodies. / Oertelt, Sabine; Podda, Mauro; Gershwin, M. Eric.

Autoantibodies. Elsevier Inc., 2007. p. 135-139.

Research output: Chapter in Book/Report/Conference proceedingChapter

Oertelt, S, Podda, M & Gershwin, ME 2007, Antinucleolar antibodies. in Autoantibodies. Elsevier Inc., pp. 135-139. https://doi.org/10.1016/B978-044452763-9/50022-6
Oertelt S, Podda M, Gershwin ME. Antinucleolar antibodies. In Autoantibodies. Elsevier Inc. 2007. p. 135-139 https://doi.org/10.1016/B978-044452763-9/50022-6
Oertelt, Sabine ; Podda, Mauro ; Gershwin, M. Eric. / Antinucleolar antibodies. Autoantibodies. Elsevier Inc., 2007. pp. 135-139
@inbook{d93345c441ca4acf924053985cf0a184,
title = "Antinucleolar antibodies",
abstract = "Antinucleolar antibodies (ANoAs) react against a wide range of nucleolar structures, virtually targeting every functional step of ribosomal transcription. Traditionally detected by immunofluorescence, their presence is confirmed by immunoprecipitation and in some cases by Enzyme-linked immunosorbent assay (ELISA). The patterns detected by immunofluorescence are: speckled, associated with reactivity against RNA polymerase; homogeneous, characteristic of anti-PM-Scl and anti-To/Th antibody positivity; and clumpy, observed in cells in metaphase and associated with antibodies against snoRNPs. ANoAs are prevalently associated with systemic sclerosis (SSc), but are detectable in small numbers of patients with other autoimmune diseases and carcinomas. The prevalence of different ANoAs in the serum of patients with SSc varies, but never exceeds 20-30{\%}, making these antibodies not useful for primary diagnosis of the disease. Nonetheless, specific clinical associations for various subtypes of ANoAs suggest that these antibodies are potentially valuable diagnostic markers, especially for high-risk patient groups.",
author = "Sabine Oertelt and Mauro Podda and Gershwin, {M. Eric}",
year = "2007",
doi = "10.1016/B978-044452763-9/50022-6",
language = "English (US)",
isbn = "9780444527639",
pages = "135--139",
booktitle = "Autoantibodies",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Antinucleolar antibodies

AU - Oertelt, Sabine

AU - Podda, Mauro

AU - Gershwin, M. Eric

PY - 2007

Y1 - 2007

N2 - Antinucleolar antibodies (ANoAs) react against a wide range of nucleolar structures, virtually targeting every functional step of ribosomal transcription. Traditionally detected by immunofluorescence, their presence is confirmed by immunoprecipitation and in some cases by Enzyme-linked immunosorbent assay (ELISA). The patterns detected by immunofluorescence are: speckled, associated with reactivity against RNA polymerase; homogeneous, characteristic of anti-PM-Scl and anti-To/Th antibody positivity; and clumpy, observed in cells in metaphase and associated with antibodies against snoRNPs. ANoAs are prevalently associated with systemic sclerosis (SSc), but are detectable in small numbers of patients with other autoimmune diseases and carcinomas. The prevalence of different ANoAs in the serum of patients with SSc varies, but never exceeds 20-30%, making these antibodies not useful for primary diagnosis of the disease. Nonetheless, specific clinical associations for various subtypes of ANoAs suggest that these antibodies are potentially valuable diagnostic markers, especially for high-risk patient groups.

AB - Antinucleolar antibodies (ANoAs) react against a wide range of nucleolar structures, virtually targeting every functional step of ribosomal transcription. Traditionally detected by immunofluorescence, their presence is confirmed by immunoprecipitation and in some cases by Enzyme-linked immunosorbent assay (ELISA). The patterns detected by immunofluorescence are: speckled, associated with reactivity against RNA polymerase; homogeneous, characteristic of anti-PM-Scl and anti-To/Th antibody positivity; and clumpy, observed in cells in metaphase and associated with antibodies against snoRNPs. ANoAs are prevalently associated with systemic sclerosis (SSc), but are detectable in small numbers of patients with other autoimmune diseases and carcinomas. The prevalence of different ANoAs in the serum of patients with SSc varies, but never exceeds 20-30%, making these antibodies not useful for primary diagnosis of the disease. Nonetheless, specific clinical associations for various subtypes of ANoAs suggest that these antibodies are potentially valuable diagnostic markers, especially for high-risk patient groups.

UR - http://www.scopus.com/inward/record.url?scp=61349101543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349101543&partnerID=8YFLogxK

U2 - 10.1016/B978-044452763-9/50022-6

DO - 10.1016/B978-044452763-9/50022-6

M3 - Chapter

SN - 9780444527639

SP - 135

EP - 139

BT - Autoantibodies

PB - Elsevier Inc.

ER -